Pacific Shuanglin Bio pharmacy Co Ltd (SHE:000403) — Market Cap & Net Worth
Market Cap & Net Worth: Pacific Shuanglin Bio pharmacy Co Ltd (000403)
Pacific Shuanglin Bio pharmacy Co Ltd (SHE:000403) has a market capitalization of $1.50 Billion (CN¥10.27 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #7365 globally and #1700 in its home market, demonstrating a -9.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pacific Shuanglin Bio pharmacy Co Ltd's stock price CN¥10.81 by its total outstanding shares 950397386 (950.40 Million). Review Pacific Shuanglin Bio pharmacy Co Ltd debt and liabilities to assess the company's total debt and financial obligations.
Pacific Shuanglin Bio pharmacy Co Ltd Market Cap History: 2015 to 2026
Pacific Shuanglin Bio pharmacy Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.23 Billion to $1.50 Billion (-0.38% CAGR).
Pacific Shuanglin Bio pharmacy Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pacific Shuanglin Bio pharmacy Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.72x
Pacific Shuanglin Bio pharmacy Co Ltd's market cap is 0.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.54x
Pacific Shuanglin Bio pharmacy Co Ltd's market cap is 4.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.50 Billion | $561.21 Million | $50.09 Million | 4.45x | 49.88x |
| 2017 | $2.26 Billion | $685.38 Million | $21.60 Million | 3.30x | 104.82x |
| 2018 | $1.92 Billion | $859.84 Million | $79.98 Million | 2.23x | 23.97x |
| 2019 | $2.46 Billion | $915.66 Million | $160.45 Million | 2.69x | 15.33x |
| 2020 | $5.21 Billion | $1.05 Billion | $185.97 Million | 4.96x | 28.01x |
| 2021 | $3.84 Billion | $1.97 Billion | $391.06 Million | 1.95x | 9.83x |
| 2022 | $3.13 Billion | $2.41 Billion | $587.13 Million | 1.30x | 5.33x |
| 2023 | $3.76 Billion | $2.33 Billion | $612.11 Million | 1.61x | 6.14x |
| 2024 | $2.94 Billion | $2.65 Billion | $745.32 Million | 1.11x | 3.94x |
| 2025 | $1.90 Billion | $2.63 Billion | $419.27 Million | 0.72x | 4.54x |
Competitor Companies of 000403 by Market Capitalization
Companies near Pacific Shuanglin Bio pharmacy Co Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Pacific Shuanglin Bio pharmacy Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Pacific Shuanglin Bio pharmacy Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Pacific Shuanglin Bio pharmacy Co Ltd's market cap moved from $2.23 Billion to $ 1.50 Billion, with a yearly change of -0.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.50 Billion | -21.04% |
| 2025 | CN¥1.90 Billion | -35.21% |
| 2024 | CN¥2.94 Billion | -21.84% |
| 2023 | CN¥3.76 Billion | +20.19% |
| 2022 | CN¥3.13 Billion | -18.59% |
| 2021 | CN¥3.84 Billion | -26.24% |
| 2020 | CN¥5.21 Billion | +111.81% |
| 2019 | CN¥2.46 Billion | +28.28% |
| 2018 | CN¥1.92 Billion | -15.30% |
| 2017 | CN¥2.26 Billion | -9.39% |
| 2016 | CN¥2.50 Billion | +11.83% |
| 2015 | CN¥2.23 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Pacific Shuanglin Bio pharmacy Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.50 Billion USD |
| MoneyControl | $1.50 Billion USD |
| MarketWatch | $1.50 Billion USD |
| marketcap.company | $1.50 Billion USD |
| Reuters | $1.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pacific Shuanglin Bio pharmacy Co Ltd
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen… Read more